Company intelligence / Profile preview

HRYZ Biotech

Shanghai, Shanghai, Chinashhryz.com ↗

Ownership: Private
Development stage: Other

Overview

HRYZ Biotech is a Chinese biotech company specializing in engineered T-cell therapies, particularly TCR-T cell therapies targeting solid tumors. Its lead programs are in early clinical development, with some candidates reaching Phase 2 trials for advanced cancers such as urothelial carcinoma. The company has demonstrated preclinical efficacy of its proprietary engineered TCRs against targets like AFP and HPV18 E7, with ongoing efforts to improve potency and persistence of these cellular immunotherapies.[1][3][5][8][9]

Therapeutic areas: Oncology
Modalities: TCR-T cell therapyDendritic cell vaccineTherapeutic vaccineCytotoxic T lymphocyte stimulants[1][8]
Industry: Biotech

Drug pipeline

3 assets

MASCT-I

2 more assets in the full pipeline.

Partnerships

Jiangsu Yuanzheng Cell Therapy Technology Co.Shenzhen Yuanzheng Cell Therapy Technology Co.[2]

Beyond the preview

Go deeper on HRYZ Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRYZ Biotech.